Silver Book Fact

Treatment with bisphosphonates are highly cost-effective in women over the age of 70 with osteoporosis and a previous fracture.

Fleurence R, Iglesias C, Johnson J. The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis: A structured review of the literature. PharmacoEcon. 2007; 25(11): 913-33. http://www.ncbi.nlm.nih.gov/pubmed/17960951

Reference

Title
The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis: A structured review of the literature
Publication
PharmacoEcon
Publication Date
2007
Authors
Fleurence R, Iglesias C, Johnson J
Volume & Issue
Volume 25, Issue 11
Pages
913-33
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.  
  • Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.  
  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • Clinical studies in nutrition and physical activity interventions have proven that fractures can be prevented, even in older individuals, and that they do not need to be a natural consequence…  
  • A study of a number of osteoporosis treatments found cost-effectiveness ratios as low as $55,000 per QALY.